ReviewNature reviews. Microbiology2024
Candida parapsilosis complex in the clinical setting.
Review in Nature reviews. Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 54 citations in OpenAlex.
- Outbreaks of fluconazole-resistant Candida parapsilosis are driven by low-biofilm-producing isolates that emerge under host selection.PLoS biology · 2026Article
- SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases.Mycopathologia · 2026Article
- Anandamide Targets Membrane Integrity in Non-Journal of fungi (Basel, Switzerland) · 2026Article
- Fluconazole Disk Diffusion on CHROMagar Candida Plus for Differentiation BetweenJournal of fungi (Basel, Switzerland) · 2026Article
- Captive lizards (Squamata: Sauria) as reservoirs of medically important and antifungal-resistant yeasts.Medical mycology · 2026Article
- Contrasting Biofilm-Modulating Effects of Polymeric Quaternary Ammonium Compounds on the Pathogenic YeastsACS omega · 2026Article
- Discovery of an Internal α-1,3-Linkage-Containing Manno-Oligosaccharide in theMicroorganisms · 2026Article
- Pediatric candidemia epidemiology and antifungal susceptibility profiles reported by the ISPED program in China, 2016-2024.Antimicrobial agents and chemotherapy · 2026Article
- National Surveillance of Candidemia in the Czech Republic: Preliminary Results from the 2023 Multicentre Study.Mycopathologia · 2026Article
- Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Tolerance of outbreak-associated Candida parapsilosis isolates to antiseptics in a dry surface biofilm model.Scientific reports · 2026Article
- Reaffirming the importance of nomenclature stability forJournal of clinical microbiology · 2026Article
- Phage Display-Derived Peptides Have Neutralizing Activities Against Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2026Article
- In vitro activity of eight antifungal drugs against clinical and hospital isolates of Candida parapsilosis complex; a multicenter study, 2023-2024.BMC infectious diseases · 2026Article
- Species Identification, Virulence Factors, and Antifungal Resistance in ClinicalMicroorganisms · 2026Article
- Non-Life (Basel, Switzerland) · 2026Article
- Catechin Augments the Antifungal Efficacy of Fluconazole AgainstInternational journal of molecular sciences · 2026Article
- Catheter mechanoprophylaxis againstMicrobiology (Reading, England) · 2026Article
- Six-month surveillance ofFrontiers in cellular and infection microbiology · 2026Article
- Genetic and environmental control of parasexual reproduction in the pathogenicMicrobiology and molecular biology reviews : MMBR · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Representatives of the Candida parapsilosis complex are important yeast species causing human infections, including candidaemia as one of the leading diseases. This complex comprises C. parapsilosis, Candida orthopsilosis and Candida metapsilosis, and causes a wide range of clinical presentations from colonization to superficial and disseminated infections with a high prevalence in preterm-born infants and the potential to cause outbreaks in hospital settings. Compared with other Candida species, the C. parapsilosis complex shows high minimal inhibitory concentrations for echinocandin drugs due to a naturally occurring FKS1 polymorphism. The emergence of clonal outbreaks of strains with resistance to commonly used antifungals, such as fluconazole, is causing concern. In this Review, we present the latest medical data covering epidemiology, diagnosis, resistance and current treatment approaches for the C. parapsilosis complex. We describe its main clinical manifestations in adults and children and highlight new treatment options. We compare the three sister species, examining key elements of microbiology and clinical characteristics, including the population at risk, disease manifestation and colonization status. Finally, we provide a comprehensive resource for clinicians and researchers focusing on Candida species infections and the C. parapsilosis complex, aiming to bridge the emerging translational knowledge and future therapeutic challenges associated with this human pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.